Insider Banjak Marc buys 13,934 iBio (IBIO) shares in open market

Rhea-AI Filing Summary

iBio, Inc. insider activity: Chief Legal Officer Banjak Marc reported open-market purchases of iBio common stock. On March 26, 2026, he bought 12,500 shares at $1.6425 per share and another 1,434 shares at $1.76 per share.

After these two purchases, his directly held position increased to 25,000 shares of iBio common stock, with no sales or derivative transactions reported in this filing.

Insider Trade Summary

Net Buyer: 13,934 shares ($23,055)

Net Buy 2 txns

Insider Banjak Marc

Role Chief Legal Officer

Bought 13,934 shs ($23K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	12,500	$1.6425	$21K
Purchase	Common Stock	1,434	$1.76	$3K

Holdings After Transaction: Common Stock — 23,566 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Banjak Marc

(Last) (First) (Middle)

C/O IBIO, INC.

11750 SORRENTO VALLEY ROAD, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
iBio, Inc. [ IBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/26/2026		P		12,500	A	$1.6425	23,566	D
Common Stock	03/26/2026		P		1,434	A	$1.76	25,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Marc Banjak	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did iBio (IBIO) report for Banjak Marc?

Banjak Marc reported buying iBio shares in the open market. On March 26, 2026, the Chief Legal Officer executed two open-market purchases of common stock, increasing his direct ownership stake disclosed in this Form 4 filing.

How many iBio (IBIO) shares did Banjak Marc purchase and at what prices?

He purchased a total of 13,934 iBio common shares. The transactions were 12,500 shares at $1.6425 per share and 1,434 shares at $1.76 per share, all classified as open-market purchases under transaction code P.

What is Banjak Marc’s total iBio (IBIO) share ownership after these purchases?

Following the reported trades, Banjak Marc directly owns 25,000 shares. The Form 4 shows his total common stock holdings after the second March 26, 2026 transaction, reflecting the cumulative impact of both open-market purchases.

Were any iBio (IBIO) shares sold by Banjak Marc in this Form 4?

No sales were reported in this Form 4. Both disclosed transactions are coded P for purchases, and the transaction summary shows net-buy activity only, with zero shares classified as sales or other dispositions.

Does this iBio (IBIO) Form 4 include any option exercises or derivative trades?

No derivative transactions are listed in this Form 4. All reported activity involves non-derivative common stock, and the derivative transaction count and derivativeSummary fields both show no option exercises, conversions, or other derivative-related entries.